Clinical Trial Update: Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL [Phase 2]

View source ↗

Summary

This record describes an ongoing Phase 2 clinical trial evaluating orelabrutinib in combination with rituximab, with or without lenalidomide, for untreated marg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Marginal Zone Lymphoma(MZL) | Phase 2 | Status: RECRUITING